High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 6, 2003, Pages 1958-1962

  Yang, Shun Cheng ^a,c   Hsueh, Po Ren ^a,b   Lai, Hsin Chih ^a,b   Teng, Lee Jene ^a,b   Huang, Li Min ^a   Chen, Jong Min ^a   Wang, Shu Kuan ^a   Shie, Der Chuen ^a   Ho, Shen Wu ^a,b   Luh, Kwen Tay ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RNA 16S; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BACTERIUM ISOLATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NONHUMAN; PRIORITY JOURNAL; RNA GENE; TAIWAN;

ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS; POLYMERASE CHAIN REACTION; RNA, RIBOSOMAL, 16S; TAIWAN;

EID: 0037764104     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.6.1958-1962.2003     Document Type: Article

References (32)

1. Brown-Elliott, B. A., and R. J. Wallace, Jr. 2002. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin. Microbiol. Rev. 15:716-746.
2. Brown-Elliott, B. A., R. J. Wallace, Jr., R. Blinkhorn, C. J. Crist, and L. B. Mann. 2001. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin. Infect. Dis. 33:1433-1434.
3. Brown-Elliott, B. A., R. J. Wallace, Jr., C. J. Crist, L. B. Mann, and R. W. Wilson. 2002. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob. Agents Chemother. 46:3283-3285.
4. Brown-Elliott, B. A., R. J. Wallace, Jr., G. O. Onyi, V. De Rosas, and R. J. Wallace III. 1992. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob. Agents Chemother. 36:180-184.
5. Casal, M., and F. Rodriguez. 1983. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonae to sisomicin, gentamicin, and tobramycin. Ann. Microbiol. 134B:451-454.
6. Dalovisio, J. R., and G. A. Pankey. 1978. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonae to amikacin. J. Infect. Dis. 137:318-321.
7. Debrunner, M., M. Salfinger, O. Brandli, and A. von Gravenitz. 1992. Epidemiology and clinical significance of nontuberculous mycobacteria in patients negative for human immunodeficiency virus in Switzerland. Clin. Infect. Dis. 15:330-345.
8. Fernandez-Roblas, R., J. Esteban, F. Cabria, J. C. Lopez, M. S. Jimenez, and F. Soriano. 2000. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob. Agents Chemother. 44:181-182.
9. Hsueh, P. R., L. J. Teng, P. C. Yang, Y. C. Chen, S. W. Ho, and K. T. Luh. 1998. Recurrent catheter-related infection caused by a single clone of Mycobacterium chelonae with two clonal morphotypes. J. Clin. Microbiol. 36:1422-1424.
10. Metchock, B. G., F. S. Nolte, and R. J. Wallace, Jr. 1999. Mycobacterium, p. 399-437. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
11. Meyers, H., B. A. Brown-Elliott, D. Moore, J. Curry, C. Truong, Y. Zhang, and R. J. Wallace, Jr. 2002. An outbreak of Mycobacterium chelonae infection following liposuction. Clin. Infect. Dis. 34:1500-1507.
12. National Committee for Clinical Laboratory Standards. 2002. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Tentative standards-second edition. M24-T2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Shih, J. Y., P. R. Hsueh, L. N. Lee, H. C. Wang, P. C. Yang, S. H. Kuo, and K. T. Luh. 1997. Nontuberculous mycobacteria isolates: clinical significance and disease spectrum. J. Formos. Med. Assoc. 96:621-627.
15. Silcox, V. A., R. C. Good, and M. M. Floyd. 1981. Identification of clinically significant Mycobacterium fortuitum complex isolates. J. Clin. Microbiol. 14:686-691.
16. Steingrube, V. A., J. L. Gibson, B. A. Brown, Y. Zhang, R. W. Wilson, M. Rajagopalan, and R. J. Wallace, Jr. 1995. PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. J. Clin. Microbiol. 33:149-153.
17. Swenson, J. M., C. Thornsberry, and V. A. Silcox. 1982. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob. Agents Chemother. 22:186-192.
18. Swenson, J. M., R. J. Wallace, Jr., V. A. Silcox, and C. Thornsberry. 1985. Antimicrobial susceptibility testing of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother. 28:807-811.
19. Turenne, C. Y., L. Tschetter, J. Wolfe, and A. Kabani. 2001. Necessity of quality-controlled 16S rRNA gene sequence databases: identifying nontuberculous Mycobacterium species. J. Clin. Microbiol. 39:3637-3648.
20. Wallace, R. J., Jr., J. M. Swenson, V. A. Silcox, and M. G. Bullen. 1985. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonae on the basis of in vitro susceptibilities. J. Infect. Dis. 152:500-514.
21. Wallace, R. J., Jr., J. Glassroth, D. E. Griffith, K. N. Olivier, J. L. Cook, and F. Gordin. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society statement. Am. J. Respir. Crit. Care Med. 156:S1-S25.
22. Wallace, R. J., Jr., B. A. Brown, G. O. Onyi. 1992. Skin, soft tissue, and bone infections due to Mycobacterium chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J. Infect. Dis. 166:405-412.
23. Wallace, R. J., Jr., B. A. Brown, and G. Onyi. 1991. Susceptibilities of Mycobacterium fortuitum biovar fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob. Agents Chemother. 35:773-775.
24. Wallace, R. J., Jr., D. B. Jones, and K. Wiss. 1981. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonae. Rev. Infect. Dis. 3:898-904.
25. Wallace, R. J., Jr., G. Bedsole, G. Sumter, C. V. Sanders, L. C. Steele, B. A. Brown, J. Smith, and D. R. Graham. 1990. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob. Agents Chemother. 35:65-70.
26. Wallace, R. J., Jr., B. A. Brown-Elliott, S. C. Ward, C. J. Crist, L. B. Mann, and R. W. Wilson. 2001. Activities of linezolid against rapidly growing mycobacteria. Antimicrob. Agents Chemother. 45:764-767.
27. Wallace, R. J., Jr., A. Meier, B. A. Brown, Y. Zhang, P. Sander, G. O. Onyi, and E. C. Bottger. 1996. Genetic basis for clarithromycin resistance among isolates Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40:1676-1681.
28. Wallace, R. J., Jr., B. A. Brown-Elliott, C. J. Crist, L. B. Mann, and R. W. Wilson. 2002. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 46:3164-3167.
29. Wallace, R. J., Jr., B. A. Brown-Elliott, L. Hall, G. Roberts, R. W. Wilson, L. B. Mann, C. J. Crist, S. H. Chiu, R. Dunlap, M. J. Garcia, J. T. Bagwell, and K. C. Jost, Jr. 2002. Clinical and laboratory features of Mycobacterium mageritense. J. Clin. Microbiol. 40:2930-2935.
30. Wang, H. C., Y. S. Liaw, P. C. Yang, S. H. Kuo, and K. T. Luh. 1995. A pseudoepidemic of Mycobacterium chelonae infection caused by contamination of a fibreoptic bronchoscope suction channel. Eur. Respir. J. 8:1259-1262.
31. Wilson, R. W., V. A. Steingrube, E. C. Bottger, B. Springer, B. A. Brown-Elliott, V. Vincent, K. C. Jost, Jr., Y. Zhang, M. J. Garcia, S. H. Chiu, G. O. Onyi, H. Rossmoore, D. R. Nash, and R. J. Wallace, Jr. 2001. Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks and contaminated metalworking fluids: an international cooperative study on mycobacterial taxonomy. Int. J. Syst. Evol. Microbiol. 51:1751-1764.
32. Woods, G. L., J. S. Bergmann, F. G. Witebsky, G. A. Fahle, A. Wanger, B. Boulet, M. Planunt, B. A. Brown, and R. J. Wallace, Jr. 1999. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 37:1676-1682.